For years, the worldwide pharmaceutical stage has been dominated by the giant pharmaceutical companies of North America and Europe. With the exception of Japan, now a major player, medicinal drug production has been concentrated in the U.S., Germany, France, and the UK. Given a global market size approaching a trillion dollars, the pharmaceutical market represents an irresistible opportunity that is now being pursued by other parts of world. China and India represent huge markets for lower-end pharmaceuticals, and the African pharmaceutical market is approaching $30 billion. Having hundreds of millions of people dependent upon a relative handful of countries and producers has become a source of concern for many governments.
In Russia, the government has taken the situation so seriously that it has pursued a number of programs to encourage the growth of its own pharmaceutical industry. In 2010, Russia’s then-President Dmitry Medvedev called for measures to further develop the domestic pharmaceutical industry and reduce the country’s dependence on foreign medicine. The initiative was echoed a year later by Vladimir Putin. Plans now call for $39 billion in financing in support of biotechnology under the umbrella of what is called the “The Comprehensive Program for Development of Biotechnology in the Russian Federation through 2020.”
Rafarma Pharmaceuticals has been one of the big beneficiaries of this movement, with the immediate result being the construction of the most technologically advanced pharmaceutical plant in Russia. The company has since been accelerating plans to produce a variety of generic pharmaceuticals, all part of the plan to greatly reduce the retail price of the most widely used drugs, freeing the country from the stranglehold of big pharma. Rafarma has, among other agreements, already been contracted for the production of the anti-cancer drug Imatinib and the anti-tuberculosis drug Para-Aminosalicylic Acid, as well as producing its own lines. The company is also actively developing a number of research and distribution agreements.
For more information, visit www.Rafarma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment